Your Search Returned 116 tagged news reports
S Published 10 March 2014 Teva Pharmaceutical Industries has launched the generic equivalent to Xeloda (capecitabine) tablets, 150mg and 500mg, in the US...Teva claims that it was the first to receive approval on its abbreviated new drug application
Eli Lilly and Co said its experimental lung cancer drug significantly improved patient survival rates compared to a placebo in a late-stage trial. The trial also showed that the drug, ramucirumab, improved survival rates without the cancer worsening.
Quebec public drug formulary for treatment earlier in advanced disease."
Alfred Hospital, while 1 to 2 additional sites are expected to be added in the near future. About 30 patients with solid tumours will be enrolled in the trial, whose primary objective is to establish the maximum tolerated dose (MTD) and dose limiting
Overall, investors, companies, and patients have seen some major advances in the oncology space...The deal Bayer and Norwegian biotech Algeta announced on Thursday morning that the two companies agreed to a proposal whereby Bayer will acquire the
The independent Data and Safety Monitoring Committee overseeing the trial recommended to the National Cancer Institute (NCI), part of NIH, that the study results be made public because a recent planned interim analysis showed prolongation in overall
Sitka Biopharma is a biotechnology company developing a new bladder cancer treatment. Sitka's technology combines a nanoparticulate drug delivery technology based on hyperbranched polyglycerols (HPG), with docetaxel, a well characterized
The trial is the second of three Phase Ib trials for vantictumab that the company intends to start in 2013 as part of its collaboration with Bayer Pharma. Primary objectives of the Phase 1b clinical trial are to assess safety of the combination
S&P Biotech Index up 41% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and companies that made waves in
Separately, the company had filed another IND under which it is carrying out clinical trials on ADI-PEG 20 to treat several other indications, including hepatocellular carcinoma. According to the company, the latter indication is already in a global